Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Suxamethonium chloride, marketed under the brand name Zycords, is a short-acting depolarizing neuromuscular blocking agent used primarily in clinical anesthesia. It functions by mimicking the action of acetylcholine at the neuromuscular junction, binding to nicotinic acetylcholine receptors and causing a prolonged depolarization of the muscle cell membrane. This persistent depolarization prevents the muscle from responding to further nerve impulses, resulting in skeletal muscle relaxation and paralysis. Its rapid onset and short duration of action make it particularly suitable for facilitating endotracheal intubation and providing muscle relaxation during brief surgical procedures or electroconvulsive therapy. It is developed and manufactured by Zydus Lifesciences.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on suxamethonium chloride.